Why Alzheimer’s drugs work in the lab but not in patients

Scientists have found that some potential gamma-secretase inhibitors such as semagacestat, which have been used in large clinical trials that ended in failure, do not function as true inhibitors as originally expected, but rather cause accumulation of toxic intraneuronal amyloid-beta. They proved this by introducing an original method to measure direct intracellular products of gamma-secretase. They commented that the application of their evaluation method may help develop truly effective drugs for Alzheimer’s disease (AD). (Mehr in: Cancer News — ScienceDaily)